Dr. Yi Luo 罗依
Chief Physician
Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Treatment of hematologic malignancies and hematopoietic stem cell transplantation.
Dr. Luo is a Chief Physician and doctoral supervisor at the Bone Marrow Transplantation Center, Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, serving since August 1995. Dr. Luo holds a PhD in Internal Medicine (Hematology) and conducts clinical and basic research on hematologic malignancies and hematopoietic stem cell transplantation.
Professional roles
- Vice Leader, Hematopoietic Stem Cell Application Group, Hematology Branch, Chinese Medical Association
- Member, Hematopoietic Stem Cell Transplantation and Cell Therapy Group, Blood and Lymphatic Professional Committee, China Anti-Cancer Association
- Vice Chair, First Youth Committee, Blood Tumor Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Hematology Branch, Zhejiang Medical Association
Name order: in Chinese the family name comes first (Luo Yi). Papers usually list the name as Yi Luo or Luo Y.
Selected publications
137 papers on PubMed matched by name and affiliation; 34 as first or senior author since 2016. Most recent first- or senior-author papers:
- Am J Ophthalmol, 2026 (senior author): Systemic Treatment With the ROCK2 Inhibitor Belumosudil in Ocular Chronic Graft-Versus-Host Disease. PubMed 42521137
- Cancer Rep (Hoboken), 2026 (senior author): Salvage Therapy With Inotuzumab Ozogamicin in Relapsed/Refractory B-ALL After CAR-T Therapy and HSCT: A Case Series. PubMed 42387626
- Cancer, 2026 (senior author): Integration of venetoclax into a fludarabine and melphalan conditioning regimen in patients aged 50 years and older with acute myeloid leukemia and myelodysplastic syndrome: Results from a phase 2 clinical trial. PubMed 42159161
- Bone Marrow Transplant, 2026 (senior author): The safety and efficacy of belumosudil and ruxolitinib combination in ruxolitinib refractory cGVHD. PubMed 41876848
- Bone Marrow Transplant, 2026 (senior author): Validation of risk stratification and novel prognostic biomarkers in asian adult HSCT recipients with TA-TMA: A multicenter real-world study. PubMed 41514049
- Cell Transplant, 2026 (senior author): Chronic graft-versus-host disease: Update on pathobiology, biomarkers, and evolving treatment algorithms. PubMed 42484488
- Cell Transplant, 2026 (senior author): Pre-transplant Clostridioides difficile infection predicts subsequent gastrointestinal GVHD and non-relapse mortality after allogeneic hematopoietic stem cell transplantation. PubMed 42287211
- Cell Transplant, 2026 (senior author): Prognostic impact of clinico-genetic characteristics and donor types in NPM1-mutated AML undergoing allogeneic hematopoietic stem cell transplantation. PubMed 41679976
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion